Prenalterol

Prenalterol

Clinical data
Routes of administration	Oral, IV
ATC code	C01CA13 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-{[(2S)-2-hydroxy-3-(isopropylamino)propyl]oxy}phenol
CAS Number	57526-81-5 N
PubChem CID	42396
IUPHAR/BPS	537
ChemSpider	38665 Y
UNII	M4G34404CX
ChEMBL	CHEMBL1160714 Y
ECHA InfoCard	100.055.246
Chemical and physical data
Formula	C12H19NO3
Molar mass	225.284 g/mol
3D model (Jmol)	Interactive image
SMILES O(c1ccc(O)cc1)C[C@@H](O)CNC(C)C
InChI InChI=1S/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3/t11-/m0/s1 Y Key:ADUKCCWBEDSMEB-NSHDSACASA-N Y
NY (what is this?)

Prenalterol is a cardiac stimulant which acts as a β₁ adrenoreceptor agonist.

Prenalterol interestingly exhibits adrenergic agonist activity in spite of an interposed oxymethylene group. The stereospecific synthesis devised for this molecule relies on the fact that the side chain is very similar in oxidation state to that of a sugar.

Condensation of monobenzone (2) with the epoxide derived from α-D-glucofuranose affords the glycosylated derivative (3). Hydrolytic removal of the acetonide protecting groups followed by cleavage of the sugar with periodate gives aldehyde (4). This is reduced to the glycol by means of NaBH₄ and the terminal alcohol is converted to the mesylate (5). Displacement of the leaving group with isopropylamine followed by hydrogenolytic removal of the O-benzyl ether affords the β₁-adrenergic selective adrenergic agonist prenalterol (6).

Prepns of the racemic mixture: NL 6409883  corresp to H. Köppe et al., U.S. Patent 3,637,852 (1965, 1972 both to Boehringer Ingelheim); NL 301580  corresp to A. F. Crowther, L. H. Smith, U.S. Patent 3,501,769 (1965, 1970 both to ICI);